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Abstract
The purpose of this study was to investigate the effects of diabetes on mesenchymal stem cells 
(MSCs) in terms of their angiogenic and therapeutic potential for repairing tissue ischemia. We 
culture-isolated MSCs from streptozotocin-induced diabetic rats (D-MSCs) and compared their 
proliferation, differentiation, and angiogenic effects with those from normal rats (N-MSCs). The 
angiogenic effects of MSCs were evaluated by real-time PCR, in vitro tube formation assay, and 
transplantation of the MSCs into a hindlimb ischemia model followed by laser Doppler perfusion 
imaging. The number of MSCs derived from diabetic rats was smaller, and their proliferation rate 
was slower than N-MSCs. Upon induction of differentiation, the osteogenic and angiogenic 
differentiation of D-MSCs were aberrant compared to N-MSCs. The expression of angiogenic 
factors was lower in D-MSCs than N-MSCs. D-MSCs cocultured with endothelial cells resulted in 
decreased tube formation compared to N-MSCs. D-MSCs were ineffective to improve hindlimb 
ischemia and showed lower capillary density and angiogenic gene expression in ischemic limbs 
than N-MSCs. D-MSCs have defective proliferation and angiogenic activities and are ineffective 
for repairing hindlimb ischemia. Newer measures are needed before MSCs can be employed as a 
source for autologous cell therapy.
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INTRODUCTION
Diabetes mellitus is a major risk factor for cardiovascular disease (17). Cardiovascular 
disease is the principal cause of death in diabetic patients, accounting for about 50% of all 
diabetes fatalities (49). As the number of people with diabetes worldwide is expected to 
increase from 171 million in 2000 to 366 million by 2030 (57), cardiovascular disease in 
diabetic patients is rapidly emerging as a global health care problem (17,57). In addition to 
cardiovascular diseases, diabetic patients have a higher risk of developing bone fracture, 
wound healing problems, nephropathy, and retinopathy (22,56).
Mesenchymal stem cells (MSCs), also known as multi-potent stromal cells, hold great 
promise for treating intractable diseases because they are easily expandable and can 
differentiate into various cell types, including osteoblasts, chondrocytes, and adipocytes 
(44,55). MSCs also secrete various angiogenic and cell survival factors and were shown to 
be effective for treating ischemic cardiovascular diseases and diabetic complications in 
animal models and human patients (15,28,30–32,34,36,58). However, the proliferation and 
differentiation capacity of MSCs derived from diabetic patients have yet to be determined.
Although MSCs are known to be less immunogenic than other cells when transplanted into 
nonautologous recipients, allogeneic approaches for cell therapy have clear limitations due 
to the immunological reactions and the possibility of disease transmission. Thus, an 
autologous approach using MSCs for cell therapy would be more optimal. However, MSCs 
derived from subjects having cardiovascular risk factors have been poorly characterized. All 
the studies using MSCs for treatment of cardiovascular diseases were conducted with MSCs 
obtained from healthy subjects, and little is known about the effects of diabetes on MSCs. 
Given that diabetic patients are more prone to advanced cardiovascular diseases, cell therapy 
is likely to be more beneficial. It is crucial to elucidate the effects of diabetes on MSCs, 
particularly from the standpoint of their angiogenic and ischemic tissue-repairing potential.
In fact, recent studies have shown that other bone marrow (BM)-derived cells such as 
endothelial progenitor cells (EPCs) (7,37,53,54) and BM-mononuclear cells (MNCs) (52) 
isolated from diabetic subjects are defective in their angiogenic activities and are ineffective 
in the treatment of ischemic cardiovascular diseases. However, it was unknown whether 
diabetic MSCs have impaired angiogenic activities and reduced therapeutic effects on 
ischemic diseases.
Here we investigated the characteristics of BM-derived MSCs from diabetic rats (D-MSCs) 
focusing on their in vitro proliferation and multilineage differentiation capability, in vitro 
and in vivo angiogenic effects, and their revascularizing effects. This study demonstrated 
that D-MSCs had aberrant cell biologic characteristics, reduced angiogenic effects, and 
impaired therapeutic effects in recovering limb ischemia.
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MATERIALS AND METHODS
Induction of Diabetes Mellitus
All protocols for animal experiments were approved by the Institutional Animal Care and 
Use Committees of St. Elizabeth Medical Center and Emory University and conformed to 
the National Institutes of Health Guide for the Care and Use of Laboratory Animals. We 
induced diabetes in 8-week-old male Fischer 344 rats (Harlan, Indianapolis, IN, USA) by 
intravenous injection of streptozotocin (65 mg/kg; Sigma-Aldrich, St. Louis, MO, USA). 
Blood glucose levels were measured using an Accu-Check glucometer (Roche Diagnostics, 
Indianapolis, IN, USA) after 1 week and 2 months. If blood glucose was higher than 200 
mg/dl, rats were considered diabetic. Rats with glucose levels lower than 200 mg/dl were 
excluded from the study. Age- and sex-matched normal rats were used as controls.
MSC Culture
Two months after induction of diabetes using streptozotocin (Sigma-Aldrich), BMMNCs 
were isolated as previously described (26) using HISTOPAQUE®-1083 (Sigma-Aldrich) 
according to the manufacturer’s instructions. Whole BMMNCs were plated in Minimum 
Essential Media-α media (Life Technologies, Grand Island, NY, USA) supplemented with 
20% FBS and 1% antibiotics (all from Life Technologies; final concentration: 100 U/ml 
penicillin and 100 µg/ml streptomycin). After 3 days of incubation in a humidified incubator 
at 37°C with 5% CO2, nonadherent hematopoietic cells were removed by changing the 
media. The adherent cells were further cultured as previously described, (35) and their MSC 
identity was confirmed by flow cytometry analysis using anti-CD29-APC (1:100; BD 
Biosciences, San Jose, CA, USA), anti-CD44-PE (1:100; BD Biosciences), anti-CD90-PE 
(1:100; eBioscience, San Diego, CA, USA), and anti-CD45-PE (1:100; BD Biosciences) 
antibody (4,33). MSCs in passages two to four were used for study.
MSC Proliferation and Colony Forming Unit Assay
For the cell proliferation assay, MSCs were plated at 200 cells/cm2, and the number of 
resultant cells was determined. To evaluate proliferative cells, immunocytochemistry with 
anti-Ki-67 antibody (EMD Millipore, Billerica, MA, USA) was performed. For the colony-
forming unit assay, 100 MSCs were plated onto 100-mm dishes (Falcon®; Corning, 
Corning, NY, USA) and cultured for 14 days. The cells were stained with crystal violet 
(Sigma-Aldrich), and the number of colonies were counted as previously described (12).
Differentiation of MSCs
Osteogenic differentiation of MSCs was induced using osteogenic medium as previously 
described (21,43,44). Briefly, MSCs were plated at a density of 3,000 cells/cm2 in six-well 
plates and cultured in osteogenic induction medium [low-glucose DMEM (Life 
Technologies) supplemented with 100 nM dexamethasone (Sigma-Aldrich), 10 mM β-
glycerophosphate (Sigma-Aldrich), 0.05 mM L-ascorbic acid-2-phosphate (Sigma-Aldrich), 
10% FBS (Life Technologies), and 1% antibiotics (Life Technologies)] for 2 weeks. von 
Kossa (Abcam, Cambridge, UK) staining (21) and quantification of calcium was performed 
as previously described (19,27). Adipogenic differentiation of MSCs was induced using 
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adipogenic induction and maintenance media as previously described (44,47). Briefly, 
MSCs were plated at a density of 10,000 cells/cm2 in six-well plates (Costar®; Corning). 
After confluence, the cells were cultured for an additional 5 days and cultured in adipogenic 
induction medium [high-glucose DMEM supplemented with 1 mM dexamethasone, 0.5 mM 
methyl-isobutylxanthine (Sigma-Aldrich), 10 µg/ml insulin (Sigma-Aldrich), 100 mM 
indomethacin (Sigma-Aldrich), 10% FBS, and 1% antibiotics] for 2 days and in adipogenic 
maintenance medium (high-glucose DMEM supplemented with 10 µg/ml insulin, 10% FBS, 
and 1% antibiotics) for 2 days. After two more cycles of culture in adipogenic induction and 
maintenance media, cells were cultured in adipogenic maintenance media until analyzed. 
The level of adipogenic differentiation was determined by Oil red O (Sigma-Aldrich) 
staining as previously described (44,46,47). Briefly, the cells were fixed using 10% formalin 
(Sigma-Aldrich) and stained using 3 mg/ml Oil red O solution in 60% isopropanol. After 
rinsing with 60% isopropanol, the cells were counterstained using hematoxylin (Sigma-
Aldrich).
Quantitative Real-Time RT-PCR
Total RNA was extracted from tissue or cells with TRIzol® (Life Technologies) according 
to the manufacturer’s instructions. The tissues were collected from the hindlimbs at 2 weeks 
after cell transplantation. First-strand cDNA was generated using the TaqMan® Multiscribe 
Reverse Transcription Kit (Life Technologies) primed with a mix of oligo dT and random 
hexamers. Gene expression was determined by TaqMan® real-time quantitative PCR on the 
7300 Sequence Detection System (Life Technologies) using TaqMan® PCR Master Mix 
(Life Technologies). Relative mRNA expression of target gene normalized to GAPDH was 
calculated using the formula Relative Expression Level = 2−ΔCT, where ΔCT = CT gene of 
interest −CT GAPDH as previously described (25). The primers and probes were designed 
using Primer Express 3.0 (Life Technologies) and are described in Table 1.
Tube Formation Assay
Glass chamber slides (Nunc™ Lab-Tek™ II; Thermo Scientific, Waltham, MA, USA) were 
coated with Matrigel™ (BD Biosciences) and overlaid with 7 × 104 human umbilical vein 
endothelial cells together with 2.5 × 105 MSCs in endothelial basal medium (Lonza, Basel, 
Switzerland) in the absence of additional growth factors or cytokines and incubated at 37°C 
with 5% CO2 for 16 h. Tube formation was evaluated using a phase-contrast microscope 
(Eclipse Ti; Nikon, Tokyo, Japan).
Transplantation of MSCs Into Rats With Ischemic Hindlimbs
MSCs were trypsinized (Life Technologies) and labeled with DiI (Molecular Probes®; Life 
Technologies) as described by our group (23,29). Unilateral hindlimb ischemia was created 
in normal F344 rats as previously described by our group by ligating the femoral artery and 
removing all arterial branches (10,23,25,29,51). Three million DiI-labeled MSCs in 500 µl 
PBS (Cellgro®; Corning) were intramuscularly injected into the ischemic hindlimbs.
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Blood Flow Measurement in Hindlimbs
Blood flow in the hindlimb was measured using a Laser Doppler perfusion imager (LDPI; 
Moor Instrument, Delaware, DE, USA) as previously described (10,23,25, 29,51). Mean 
values of perfusion were calculated from the stored digital color-coded images. The level of 
blood flow of the ischemic (left) limb was normalized to that of the nonischemic (right) limb 
to avoid data variations caused by ambient light and temperature as we previously described 
(10,23,25,29,51).
Measurement of Capillary Density
Four weeks after the injection of N- or D-MSCs into ischemic hindlimbs, the hindlimb 
muscles were harvested, fixed with 4% paraformaldehyde (Sigma-Aldrich) at 4°C overnight, 
and frozen in OCT compound (Tissue-Tek®; Sakura Finetek USA, Torrance, CA, USA) and 
cryosectioned at 10-µm intervals using cryostat (Cryotome FE/FSE; Thermo Scientific). To 
visualize capillaries, the sections were stained using isolectin B4 (Vector Laboratories, 
Burlingame, CA, USA) (9,23,25,29), and the capillary density was determined under 
conventional epifluorescence microscopy (Eclipse Ti; Nikon) as previously described 
(9,23,25,29).
Western Blotting of AKT1
Western blots were performed as described previously (61) using monoclonal antibody 
against AKT1 (1:500; Cell Signaling Technology, Danvers, MA, USA) and phosphorylated 
AKT1 (1:500; Cell Signaling Technology). Densitometric analyses for the blots were 
performed using ImageJ software (National Institutes of Health, Bethesda, MD, USA).
Statistical Analysis
All results were expressed as a mean value ± SEM. Statistical analysis was performed by 
Student’s t-test for comparisons between two groups and repeated-measures ANOVA for 
more than two groups followed by Tukey’s multiple comparison test using GraphPad Prism 
(GraphPad Software, La Jolla, CA, USA). A value of p < 0.05 was considered to be 
statistically significant.
RESULTS
Fewer MSCs Are Culture-Isolated From Diabetic Than Normal Rats
Hyperglycemia was induced by the injection of streptozotocin in the rats (Table 2). 
BMMNCs were isolated from normal and diabetic rats and subjected to MSC culture. Most 
of the adherent cells from normal BM were spindle or satellite shaped, whereas many of the 
adherent cells from diabetic BM were round (Fig. 1A). The number of adherent cells was 
33% less in diabetic rats compared to normal rats (p < 0.05) at day 4 after culture of BM 
(Fig. 1B).
The Proliferation of D-MSCs Is Impaired
We next determined the proliferation potential of diabetic MSCs. Normal or diabetic MSCs 
were plated at 200 cells/cm2, and the cell number was determined by cell counting every 
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day. The cell number became significantly smaller in D-MSCs than in N-MSCs from day 7, 
and the difference became greater over the next 5 days (Fig. 1C). Furthermore, we 
performed Ki-67 staining to verify these results. The number of Ki-67-positive cells was 
53% lower in D-MSCs compared to N-MSCs (Fig. 2). To determine whether this was due to 
slow proliferation of D-MSCs compared to N-MSCs, we performed a colony-forming unit 
assay, which determines actively proliferating cell portions. The number of colony-forming 
units was 18% smaller in D-MSCs compared to N-MSCs (p < 0.05) (Fig. 1D), suggesting 
that the proportion of actively proliferating cells is smaller in D-MSCs than N-MSCs. This 
impaired proliferation of D-MSCs indicates that the self-renewal potential of D-MSCs is 
lower compared to N-MSCs. We next examined expression of the surface epitopes in these 
cells. Flow cytometry analysis demonstrated that the adherent cells derived from both 
normal or diabetic rats expressed typical MSC markers, such as CD29, CD44, and CD90, 
but not a pan-hematopoietic cell marker, CD45 (Fig. 3), confirming that these cells are 
MSCs regardless of diabetic status.
D-MSCs Have Aberrant Differentiation Propensity
To determine whether diabetic conditions affect the differentiation propensity of MSCs, we 
exposed the N- or D-MSCs to known osteogenic and adipogenic differentiation conditions. 
After N- or D-MSCs were induced to differentiate into the osteogenic lineage, we performed 
von Kossa staining, which stains mineralized bone tissue with a black color. Whereas a 
significant proportion of N-MSCs were positive for von Kossa staining, no D-MSCs were 
(Fig. 4A). When we quantified the level of osteogenic differentiation by determining the 
calcium deposition, the amount of deposited calcium was more than fivefold lower in D-
MSCs than in N-MSCs (p < 0.01) (Fig. 4B), indicating that the osteogenic differentiation 
potential of D-MSCs is impaired.
To evaluate their adipogenic differentiation potential, we exposed N- or D-MSCs to well-
known adipogenic differentiation conditions for 3 weeks and stained cells with Oil red O 
staining, which stains intracellular lipid with a dark color. D-MSCs showed higher numbers 
of Oil red O-stained cells than N-MSCs (Fig. 4C), suggesting that D-MSCs have an 
enhanced adipogenic differentiation capability compared to N-MSCs. Taken together, the 
differentiation propensity of D-MSCs into osteogenic and adipogenic lineages are aberrant 
and the reverse of that of N-MSCs.
The Expression of Angiogenic Factors Is Lower in D-MSCs Than N-MSCs
To examine the expression levels of angiogenic genes, we isolated RNAs from N- or D-
MSCs and performed real-time RT-PCR. The expression of major angiogenic genes, such as 
vascular endothelial growth factor A (Vegfa), angiopoietin 1 (Angpt1), angiopoietin 2 
(Angpt2), vascular endothelial growth factor C (Vegfc), fibroblast growth factor 2 (Fgf2), 
placental growth factor (Pgf), and platelet-derived growth factor β polypeptide (Pdgfb) were 
significantly lower in D-MSCs than in N-MSCs, while the levels of hepatocyte growth 
factor (Hgf) and transforming growth factor, β1 (Tgfb) were not significantly different (Fig. 
5).
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D-MSCs Show Reduced Angiogenic Potential In Vitro
To determine the angiogenic capacity of D-MSCs on endothelial cells through their 
paracrine-angiogenic activities (13), we compared the tube formation capability of diabetic 
and nondiabetic MSCs in coculture with endothelial cells. We plated human umbilical vein 
endothelial cells onto Matrigel™ together with N- or D-MSCs in the absence of additional 
angiogenic factors. After 16 h, tube formation was evaluated under the microscope. The 
tubular structures were not clearly formed in the D-MSC group (Fig. 6A). Quantitatively, 
total tube length and branching points were 48% and 43% lower in the D-MSC group than 
in the N-MSC group, respectively (both p < 0.01) (Fig. 6B), suggesting that tube-forming 
ability is impaired in D-MSCs.
Implantation of D-MSCs Did Not Improve Hindlimb Ischemia In Vivo
To test the therapeutic and regenerative effects of MSCs, we injected three million N- or D-
MSCs into ischemic hindlimbs of rats and monitored blood flow using LDPI 
(23,25,29,32,41,51). PBS injection served as a control. Compared to the PBS-injected group, 
only the N-MSC-implanted group showed significantly improved blood flow (Fig. 7). 
Together, these results imply that the capacity for improving limb ischemia is impaired in D-
MSCs.
Capillary Densities Were Not Increased by Implantation of Diabetic MSCs
To further determine the neovascularization effects of D-MSCs, we quantified capillary 
density in the ischemic muscle at 4 weeks after cell implantation. MSCs were reported to 
increase capillary density through paracrine-angiogenic activities (31,32). Capillary density, 
determined by isolectin B4 (ILB4) staining, was not significantly different between the D-
MSC and PBS groups, but was 45% higher in the N-MSC-injected group compared to the 
PBS group (p < 0.01) (Fig. 8). These data indicate that in vivo angiogenic effects of D-
MSCs are impaired compared to N-MSCs.
Reduced Levels of Paracrine Factors in Ischemic Limbs Injected With D-MSCs
To investigate the changes of paracrine factors involved in neovascularization and apoptosis 
in vivo, we measured various gene expression levels by real-time RT-PCR using muscles 
harvested at 2 weeks after cell implantation. Among eight major angiogenic factors we 
selected and measured, the levels of all but insulin-like growth factor 1 (Igf) were 
significantly lower in the D-MSC group than in the N-MSC group (Fig. 9). However, Hgf, 
Fgf2, Pgf, and Angpt2 levels were higher in the D-MSC group compared to the PBS group. 
Together, these results suggest that although D-MSCs still express higher levels of certain 
angiogenic and antiapoptotic factors than the control, D-MSCs have significant impairment 
in exerting paracrine or humoral factor expression.
AKT1 Activity Is Decreased in D-MSCs Compared to N-MSCs
To further investigate the mechanisms underlying the reduced angiogenic effects of D-
MSCs, we determined the protein levels of AKT1 and phosphorylated AKT1 (pATK1) in D- 
and N-MSCs (Fig. 10A). It was shown that AKT1 function is important for paracrine effects 
and angiogenesis mediated by BM-derived stem or progenitor cells (1,38,42). However, no 
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studies investigated the effects of diabetes on AKT1 in MSCs. Western blotting analysis 
showed that the levels of pAKT1 normalized to total AKT1 were significantly lower in D-
MSCs than N-MSCs, indicating that AKT1 activity is substantially reduced in D-MSCs 
(Fig. 10B).
DISCUSSION
We demonstrated that MSCs derived from diabetic rats have significant defects in cell 
biologic, gene expression, and in vivo therapeutic effects for recovering from hindlimb 
ischemia. The salient findings of this study are as follows: First, we showed that the number 
and the proliferation rate of MSCs derived from diabetic rats were reduced compared to 
normal control rats despite a similar surface phenotype of both MSCs. Second, D-MSCs had 
an aberrant differentiation propensity, with reduced osteogenic and enhanced adipogenic 
differentiation potential compared to N-MSCs. Third, the expression of angiogenic factors 
and activity of AKT1 were reduced in D-MSCs. Fourth, implantation of D-MSCs, but not 
N-MSCs, was ineffective in recovering hindlimb ischemia.
We, for the first time, report that the neovascularizing and ischemia-recovering capabilities 
of MSCs derived from diabetic subjects are impaired. This has important clinical 
implications as the demand for cell therapy using MSCs for ischemic cardiovascular 
diseases is growing in diabetic patients. Previously, it has been reported that diabetic 
patients have decreased numbers and functionality of EPCs (7,37,53,54). Moreover, 
BMMNCs from diabetic mice were reported to have reduced ischemia-improving capacity 
(52). Both BMMNCs and EPCs were primarily isolated or short-term cultured (within 7 
days) so that the finding that the effects of diabetes remained on these cells was not so 
surprising. However, in contrast to EPCs and BMMNCs, MSCs used in this study were 
extensively expanded by ex vivo culture for at least 3 weeks at normal glucose levels. D-
MSCs used for our experiments were generated through multiple cell divisions in vitro 
under normal glucose conditions, but the defects were not repaired after cell divisions. This 
suggests that the exposure of the parent MSCs to a diabetic environment is passed onto the 
daughter cells even in a euglycemic environment over cell divisions. This is in line with the 
recent reports that high glucose can cause epigenetic changes that persist even if the cells are 
then exposed to normal glucose levels (5,14) and provides a novel insight into the effect of 
diabetic conditions on stem and progenitor cells.
It is apparent that D-MSCs have impaired paracrine activities. Given the complexities of the 
pathogenesis of diabetic cell dysfunction, it is hard to fully address the mechanisms 
underlying these paracrine defects. However, we found that AKT1 can be an important 
factor for determining such activities in diabetes. Prior studies suggested the role of AKT1 
in paracrine activities of MSCs (15,38,42) or angiogenic activities in stromal or tumor cells 
(24), but no studies have explored these roles in relation to diabetes. Our data suggest that 
AKT1 activity is decreased in D-MSCs, which may underlie the impaired paracrine and 
vessel-forming activities of the D-MSCs. Although this is one potential mechanism, further 
investigations are required to fully address the molecular mechanisms responsible for the 
effects of diabetes on MSCs.
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One study suggested a role for oxidative stress as a mechanism for impaired diabetic MSCs 
(60). This study demonstrated that type 2 diabetes induces oxidative stress and restricts the 
multipotency of MSCs, leading to impaired differentiation of MSCs into endothelial cells 
and reduced blood flow recovery after limb ischemia. Although this study and ours showed 
impaired capacity of diabetic MSCs, the study design addressed mechanisms that are quite 
dissimilar. First, that study used db/db mice, a model for type 2 diabetes, while our study 
used streptozotocin-induced diabetic rats, which is a model for type 1 diabetes. More 
importantly, the approach and the proposed mechanisms are different. In the other study, 
diabetic MSCs were transplanted into bone marrow 24 h after inducing hindlimb ischemia, 
and it was demonstrated that the mobilized MSCs from BM differentiated more into 
adipocytes than endothelial cells in the ischemic site, resulting in adipocyte infiltration in 
hindlimbs and reducing the neovascularization. Strictly speaking, this study addressed the 
pathophysiologic role of MSCs, rather than direct therapeutic effects of MSCs. Moreover, 
the effects of transdifferentiation of MSCs into endothelial cells are reported to be low (less 
than 1%) and may not explain the impaired neovascularization with MSCs (2,59). On the 
other hand, our study injected diabetic MSCs into ischemic hindlimb muscle to test their 
direct therapeutic effects and demonstrated impaired paracrine angiogenic effects of diabetic 
MSCs. Accumulating evidence suggests that the MSCs promote neovascularization mainly 
through paracrine molecules secreted by MSCs (6). In this regard, our finding reporting 
defects in paracrine factors of D-MSCs can better explain the impairment of 
neovascularization in ischemic tissue via diabetic MSCs.
Our data also showed enhanced adipogenic differentiation and reduced osteogenic 
differentiation of D-MSCs compared to N-MSCs. MSCs have been used for bone and 
adipose tissue engineering or regeneration. Diabetic patients have a higher risk for bone 
defects or fracture (11) and, thus, would have more demand for bone tissue engineering. Our 
data predict the efficacy of MSCs derived from diabetic subjects for bone and adipose tissue 
generation. In addition, the aberrant differentiation propensity of D-MSCs may also provide 
a novel mechanistic insight into the bone loss associated with diabetes. Previously, it has 
been shown that diabetic patients (11,20) and animals (50) have reduced bone mass. 
However, exact mechanisms underlying diabetic bone loss remain to be elucidated, although 
reduced osteoblastic activity without alteration in osteoclast activity and enhanced marrow 
adiposity have been reported to be involved (39). The enhanced adipogenic and reduced 
osteogenic differentiation of D-MSCs observed in our study is well in line with the above 
findings in diabetic subjects. Together, the evidence suggests that the diabetic environment 
favors adipogenic differentiation of MSCs residing in bone marrow while inhibiting their 
osteoblastic differentiation, leading to reduced bone formation.
Growing evidence has demonstrated favorable effects of MSCs on patients with acute and 
chronic cardiac dysfunction and peripheral vascular diseases (3,8,16,18,31, 32,40,45,48). 
These studies used MSCs isolated from healthy or normal donors. Although many such 
clinical studies adopted an allogeneic approach due to feasibility and cost effectiveness, an 
autologous approach is more ideal. As diabetic populations are ever increasing, particularly 
among patients with advanced cardiovascular diseases who are the most likely candidates 
for cell therapy, it is imperative to test the therapeutic potential of MSCs derived from such 
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patients or animals. This study, for the first time, suggests that MSCs derived from diabetic 
subjects have limitations in their therapeutic potential, mainly attributable to their impaired 
vessel formation capabilities. This study further emphasizes the need for new approaches 
that can restore the function of defective MSCs isolated from diabetic subjects. However, 
since we used MSCs isolated from rats, not human patients, in this study, we cannot readily 
rule out the possibility that MSCs from diabetic patients might have different therapeutic 
potential, which awaits further investigation.
In conclusion, we showed that MSCs derived from diabetic subjects have impaired cell 
biologic function and reduced neovascularization capabilities. Implantation of N-MSCs, but 
not D-MSCs, recovered hindlimb ischemia and increased vascularization in vivo. Thus, 
further investigation is required before using MSCs derived from diabetic patients for the 
treatment of ischemic cardiovascular diseases.
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Figure 1. 
Impaired proliferation of mesenchymal stem cells (MSCs) derived from diabetic rats. (A) 
Representative photomicrographs of MSC culture at 4 days. Most adherent cells from 
normal rats were spindle shaped, whereas many of those from diabetic rats (DM) were 
rounded up, suggestive of aberrancy. Scale bars: 100 µm. (B) The numbers of adherent cells, 
most of which are MSCs, were significantly higher in the normal rat group than the DM 
group (*p < 0.05, n = 3) at 10 days of culture. (C) Growth curve of MSCs. The numbers of 
MSCs were counted daily. D-MSCs showed impaired proliferation compared to N-MSCs. 
(*p < 0.05, **p < 0.01, ***p < 0.001, n = 4). (D) One hundred MSCs were plated per 100-
mm dish, and the number of colonies was counted at 14 days using crystal violet staining. 
The number of colony-forming cells was significantly lower in D-MSCs than N-MSCs (*p < 
0.05, n = 4).
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Figure 2. 
Decreased Ki-67-positive cells in D-MSCs. Culture-expanded N-MSCs and D-MSCs were 
immunostained with anti-Ki-67 antibody to examine their proliferation capacity. (A) 
Representative immunocytochemical findings for Ki-67-positive cells. The nuclei of the 
proliferating cells were demonstrated by double positivity for green (Ki-67) and blue 
fluorescence (DAPI). Scale bar: 100 µm. (B) Percentages of Ki-67-positive cells in N-MSC 
and D-MSC (**p < 0.01).
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Figure 3. 
Flow cytometric characterization of N- and D-MSCs. MSCs were culture isolated from BM 
of normal and diabetic rats. N-MSCs and D-MSCs were equally positive for MSC markers 
such as CD29, CD44, and CD90 and were negative for a pan-hematopoietic cell marker, 
CD45. Gray curves indicate the isotype controls.
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Figure 4. 
D-MSCs have aberrant differentiation propensity. von Kossa staining (A) and quantification 
of the deposited calcium (B) after osteogenic differentiation of N- or D-MSCs. D-MSCs 
showed weaker von Kossa staining and lower levels of deposited calcium than N-MSCs 
(**p < 0.01, n = 3), suggesting impaired osteogenic differentiation. (C) Oil red O staining 
after adipogenic differentiation for 3 weeks. D-MSCs showed stronger Oil red O staining 
than N-MSCs, suggesting enhanced adipogenic differentiation. Scale bars: 400 µm.
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Figure 5. 
The expression levels of angiogenic genes were lower in D-MSCs than N-MSCs. Real-time 
RT-PCR showed that the expression levels of Vegfa, Angpt1, Angpt2, Vegfc, Fgf2, Pgf, and 
Pdgfb were significantly lower in D-MSCs than N-MSCs (*p < 0.05, **p < 0.01, ***p < 
0.001), whereas the levels of Hgf and Tgfb were not significantly different between the two 
groups. n = 4–6.
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Figure 6. 
In vitro tube formation by coculture of MSCs and endothelial cells. Human umbilical vein 
endothelial cells, 7 × 104, were cocultured with 2.5 × 105 N- or D-MSCs and plated onto 
Matrigel™. Tube formation was observed after 16 h. (A) Representative photomicrographs 
showing the in vitro tube formation. (B) The total tube length and number of branching 
points of the tubular network per field were higher in the N-MSC group than the D-MSC 
group (*p < 0.05, n = 6). Scale bars: 1 mm.
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Figure 7. 
Impaired improvement of hindlimb ischemia by D-MSCs. Three million N- or D-MSCs 
were intramuscularly injected into the ischemic hindlimbs. Blood perfusion of the limb was 
determined using LDPI. Representative LDPI images (A) and quantification of the perfusion 
(B) showed that hindlimb blood flow was not significantly enhanced in the D-MSC group 
compared to the PBS group. The N-MSC group showed higher blood flow compared to the 
D-MSC group (**p < 0.01) and the PBS group (††p < 0.01). n = 5–14.
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Figure 8. 
Impaired neovascularization in hindlimb ischemia by D-MSCs. Four weeks after 
implantation of N- or D-MSCs into ischemic limbs, the limb tissues were harvested and 
stained with ILB4. Representative fluorescent micrographs (A) and quantification of the 
capillary density (B) showed that capillary density was not increased in the D-MSCs 
compared to the PBS control, but did increase in the N-MSC group compared to the D-MSC 
(**p < 0.01) and PBS groups (**p < 0.01). n = 4. Scale bars: 200 µm.
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Figure 9. 
Upregulation of angiogenic, antiapoptotic, and vessel-stabilizing factors in ischemic 
hindlimbs injected with D-MSCs and controls. The hindlimb tissues were harvested 2 weeks 
after cell implantation. Total RNA was isolated and subjected to quantitative RT-PCR. Gene 
levels were normalized to GAPDH. Data are presented as fold differences compared to the 
value of the PBS group. *p < 0.05, **p < 0.01, ***p < 0.001, n = 3–8.
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Figure 10. 
ATK1 levels in N- and D-MSCs. (A) Total proteins were isolated from N-MSCs derived 
from four normal rats and D-MSCs from five diabetic rats and subjected to Western blotting 
analysis. (B) The levels of phosphorylated AKT1 normalized to total AKT1 were lower in 
D-MSCs than in N-MSCs (*p < 0.05; n = 4 for N-MSCs, n = 5 for D-MSCs).
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Table 2
Blood Glucose Levels and Body Weights of Normal and Diabetic Rats Used in This Study (n = 16)
Normal Rats Diabetic Rats p Value
Blood glucose (mg/dl) 251 ± 49 459 ± 76 <0.001
Body weight (g) 333 ± 59 169 ± 52 <0.001
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